drugset / Trial / NCT06401213
A First-in-Human Safety Trial of MTX-463
RandomizedParallel-groupTriple-blindOther
Summary
A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-463 administered in healthy adults.
Timeline
- Start
- 2024-04-15
- Primary completion
- 2024-11-15
- Completion
- 2024-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MTX-463 | Monoclonal antibody | 4 mg/kg | — |
| Subject | MTX-463 | Monoclonal antibody | 8 mg/kg | — |
| Subject | MTX-463 | Monoclonal antibody | 16 mg/kg | — |
| Subject | MTX-463 | Monoclonal antibody | 30 mg/kg | — |
Indications
No indication recorded.